1st-course Rituximab Found to Not Trigger Antibodies in AAV Patients

1st-course Rituximab Found to Not Trigger Antibodies in AAV Patients

304675

1st-course Rituximab Found to Not Trigger Antibodies in AAV Patients

A first course of rituximab is sufficient to trigger the development of anti-rituximab antibodies in patients with systemic lupus erythematosus (SLE) but not in those with ANCA-associated vasculitis (AAV), a study found. The researchers had thought that rituximab might have similar effects in patients with SLE and AAV — both autoimmune diseases. However, the results of this study showed “the striking difference” in the occurrence of anti-drug antibodies, or ADAs, triggered by rituximab treatment across…

You must be logged in to read/download the full post.